Slides
Page 12
• • • • • • •
Page 13
• • • • • • •
Page 17
• • • • •
Page 18
• • • • • • • • • • • •
Page 22
❑ ❑ ❑
Page 23
• • • • • • • • •
Page 25
N. America EMEA APAC LatAm pharma nutrition & other crop care cellulosics PVP other • • • • •
Page 27
• • • • • • • •
Page 28
•
Page 31
• • • • • • • • • •
Page 32
Bold = advanced customer programs
Page 33
• •
Page 34
injectables Bioresorbable Polymers Other injectables
Page 36
• • • • • • •
Page 37
0 20 40 60 80 100 0 5 10 15 20 25 • • • •
Page 38
• • • • • • • • • • •
Page 39
$335M ~9% CAGR *3 additional early-stage programs
Page 40
• • • • • • • * equivalent cell survival at 10X pH neutralizer vs market leader
Page 41
• • • • • • • *15% lysis efficiency improvement at comparable concentrations (0.1%) & cell lines
Page 42
• • • • • • • • • • • • • •
Page 45
product mix1 PVP cellulosics other oral: expand offering skin: diversified growth hair: extend leadership home: purposeful growth geographic mix1 N. America EMEA APAC LatAm end market mix1 skin hair oral home applications skin care • lotions, creams & cleansers hair care • styling, cleaning, conditioning oral care • cleaning, whitening, adhesion home care • disinfection, cleansers end markets focus FY 24 reset financial highlights1 FY 24 reported financial highlights(2)(3)
Page 50
• • • •
Page 51
• • •
Page 52
✓ ✓ ✓ ✓ ✓ 0 0.2 0.4 0.6 0.8 1 -35 -25 -15 -5 0 0.5 1 1.5 2
Page 53
• • • • • •
Page 54
•
Page 55
• • • •
Page 56
0 0.05 0.1 0.15 0.2 0.25 0 20 40 60 80 100 120 140
Page 57
• • • • • •
Page 58
• • • •
Page 59
0 10,000 20,000 30,000 40,000 50,000 • • •
Page 60
0 50 100 150 200 250 300 • • •
Page 61
• • • • • •
Page 64
coatings performance specialties construction energy N. America EMEA APAC LatAm cellulosics PVP other • • • •
Page 65
• • • • • • • •
Page 66
• • • • • •
Page 67
• • •
Page 68
• • • • • •
Page 69
• • • • • • • • • • • • • • • •
Page 70
• • • • • • • •
Page 71
• • • • • • • • • • •
Page 72
• • • • •
Page 73
• • • • • • • •
Page 75
• • • • •
Page 76
• • • • • • • •
Page 77
• • • • • • • • ✓ ✓ ✓
Page 78
• • • • • • • • • • • •
Page 80
• • • • • •
Page 81
• • • • • • • • •
Page 82
• • • • • • • • 60% 65% 70% 75% 80% 85% 90% 95% 100% incumbent additive Ashland prototype 1 Ashland prototype 2 Ashland prototype 3
Page 83
• • • • • • • • • •
Page 89
• • • • • • • • • •
Page 92
• • • • • • • • + + + • • • • • • •
Page 95
Ashland Inc. and Consolidated Subsidiaries Reconciliation of Non-GAAP Data for the 12 Months Ended 1 Quarterly totals may not add to annual amounts due to rounding. Calculation of adjusted EBITDA for each period presented have been reconciled within certain financial filings with the SEC and posted on Ashland's website for each reportable segment.
Page 97
2. Calculation of adjusted EBITDA for each period presented have been reconciled within certain financial filings with the SEC and posted on Ashland's website for each reportable segment.